Imiquimod and pulmonary embolism: a case report

Area of Science:

• Dermatology
• Cardiology
• Pharmacology

Background:

• Imiquimod is a topical immune response modifier commonly used for skin conditions.
• Pulmonary embolism (PE) is a serious condition typically associated with specific risk factors.
• The patient presented with symptoms suggestive of PE.

Observation:

• A 47-year-old male patient developed bilateral pulmonary embolism.
• The patient had no known risk factors for venous thromboembolism.
• The onset of PE was possibly associated with the recent topical application of imiquimod.

Findings:

• The case report details a potential association between topical imiquimod use and the development of bilateral pulmonary embolism.
• No other predisposing factors for PE were identified in the patient.
• This suggests a possible, albeit rare, adverse reaction to imiquimod.

Implications:

• This case suggests a need for increased awareness of potential pulmonary embolism as a rare adverse effect of topical imiquimod.
• Clinicians should consider this possibility in patients using imiquimod who develop respiratory symptoms.
• Further investigation may be warranted to elucidate the mechanism of this potential association.